rs11536879
This variant is located in the TLR4 gene.
▶Research that mentions this SNP (1)
▶Sequence variants of toll-like receptor 4 (TLR4) and the risk of prostate cancer in Korean menAssociationN=463Hae Jong Kim et al.(2012)· World Journal of Urology
A case-control study of 463 Korean men (240 prostate cancer patients, 223 controls) examined 11 TLR4 gene polymorphisms for association with prostate cancer risk. The study found rs11536889 (a 3' UTR variant) was significantly associated with increased prostate cancer risk (OR=1.81, P=0.005), and the haplotype ht2 also showed significant association (OR=1.77, P=0.009). These findings suggest TLR4 polymorphisms may alter susceptibility to prostate cancer.
About TLR4
The protein encoded by this gene is a member of the Toll-like receptor (TLR) family which plays a fundamental role in pathogen recognition and activation of innate immunity. TLRs are highly conserved from Drosophila to humans and share structural and functional similarities. They recognize pathogen-associated molecular patterns that are expressed on infectious agents, and mediate the production of cytokines necessary for the development of effective immunity. The various TLRs exhibit different patterns of expression. In silico studies have found a particularly strong binding of surface TLR4 with the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus disease-2019 (COVID-19). This receptor has also been implicated in signal transduction events induced by lipopolysaccharide (LPS) found in most gram-negative bacteria. Mutations in this gene have been associated with differences in LPS responsiveness, and with susceptibility to age-related macular degeneration. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Aug 2020]
View all TLR4 variants →Gene information from NCBI Gene. Variant classifications from ClinVar.
Community Wiki
No community notes yet for this variant. Sign in to start one.
Comments
Sign in to join the discussion.
Loading comments…